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Background. Cannabis can induce transient psychotic symptoms, but not all users experience these adverse eﬀects.
We compared the neural response to D9-tetrahydrocannabinol (THC) in healthy volunteers in whom the drug did or
did not induce acute psychotic symptoms.
Method. In a double-blind, placebo-controlled, pseudorandomized design, 21 healthy men with minimal experience
of cannabis were given either 10 mg THC or placebo, orally. Behavioural and functional magnetic resonance imaging
measures were then recorded whilst they performed a go/no-go task.
Results. The sample was subdivided on the basis of the Positive and Negative Syndrome Scale positive score
following administration of THC into transiently psychotic (TP ; n=11) and non-psychotic (NP ; n=10) groups.
During the THC condition, TP subjects made more frequent inhibition errors than the NP group and showed
diﬀerential activation relative to the NP group in the left parahippocampal gyrus, the left and right middle temporal
gyri and in the right cerebellum. In these regions, THC had opposite eﬀects on activation relative to placebo in the
two groups. The TP group also showed less activation than the NP group in the right middle temporal gyrus and
cerebellum, independent of the eﬀects of THC.
Conclusions. In this ﬁrst demonstration of inter-subject variability in sensitivity to the psychotogenic eﬀects of THC,
we found that the presence of acute psychotic symptoms was associated with a diﬀerential eﬀect of THC on
activation in the ventral and medial temporal cortex and cerebellum, suggesting that these regions mediate the eﬀects
of the drug on psychotic symptoms.
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Introduction
Epidemiological research points towards a link be-
tween the use of cannabis and the increased risk of
developing a psychotic illness, in a dose-dependent
manner (Arseneault et al. 2002 ; Zammit et al. 2002 ;
Moore et al. 2007). However, cannabis aﬀects in-
dividuals diﬀerently and not everyone who uses
it develops psychosis. The basis of this variable
sensitivity is unclear, as is the location where
D9-tetrahydrocannabinol (THC), the main compound
of the plant, mediates its psychotogenic eﬀects.
Individuals with a predisposition to psychosis who
might be particularly vulnerable to its adverse eﬀects
were indicated by a positive family history of psy-
chosis (McGuire et al. 1995), a schizotypal personality
(Stirling et al. 2008), the presence of subclinical psy-
chotic features (Henquet et al. 2004), being at ultra-
high risk for psychosis (Peters et al. 2009) or carrying
speciﬁc genes (Caspi et al. 2005; van Winkel et al. 2011;
Bhattacharyya et al. 2012a).
Elucidating which behavioural and biological fac-
tors confer greater risk for psychosis in cannabis users
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is crucial, because as the availability of plants with
higher THC content has increased, so have the related
health risks (Degenhardt et al. 2010 ; Cascini et al. 2011).
Although relatively few individuals develop a full-
blown psychotic illness after cannabis use, a larger
number (between 15 and 51%) experience transient
psychotic symptoms lasting from a few hours to a few
days, as a result of cannabis use (Thomas, 1996 ; Green
et al. 2003 ; D’Souza et al. 2004, 2009 ; Morrison et al.
2009). It is not yet known if there is a continuum of risk
between those who become transiently psychotic (TP)
and those who develop an enduring psychotic illness
in relation to cannabis use. However, it would be both
logical and ethically feasible to study the eﬀects of
THC in healthy individuals by comparing those who
experience transient psychotic symptoms due to can-
nabis intoxication with those who do not. Findings
may inform research on the mechanisms underlying
psychotic symptoms per se, as well as examining
behavioural and neurobiological mechanisms that
increase the potential risk to an individual.
Although there are a growing number of neuro-
imaging studies that have examined the acute eﬀects of
THC administration on brain function (Martı´n-Santos
et al. 2010), including those from our group (Borgwardt
et al. 2008; Fusar-Poli et al. 2009; Bhattacharyya et al.
2009, 2010; Winton-Brown et al. 2011), to date
none of these studies has examined the eﬀects of THC
according to psychotic symptom outcome.
Response inhibition, the ability to suppress irrel-
evant acts, is a function that is impaired in cannabis
users, since they make more inhibitory errors (Hester
et al. 2009 ; Ramaekers et al. 2009 ; Battisti et al. 2010a). It
is also relevant to patients with schizophrenia who are
reported to perform slowly in various response inhi-
bition tasks (Enticott et al. 2008; Huddy et al. 2009) and
have poor error awareness (Turken et al. 2003).
Furthermore, this group shows abnormal fronto-
striatal activation during inhibition tasks (Rubia et al.
2001a). A well-established response inhibition para-
digm used in imaging studies is the go/no-go task,
which involves the activation of the inferior frontal
cortex (IFC), dorsolateral prefrontal cortex (DLPFC),
inferior parietal cortices and anterior cingulate gyrus
(ACG) (Rubia et al. 2001b ; Simmonds et al. 2008).
The neuroimaging ﬁndings regarding the eﬀect of
cannabis on response inhibition are inconclusive due
to methodological variations. Two studies report sig-
niﬁcantly lower activation in regular cannabis users,
relative to non-users, within the ACG and diﬀuse
bilateral activity in the DLPFC (Gruber & Yurgelun-
Todd, 2005; Hester et al. 2009). Another study reports
increased response in the right DLPFC, bilateral
medial frontal, inferior and superior parietal lobules
in cannabis users even after 28 days of monitored
abstinence (Tapert et al. 2007). In our previous study
on response inhibition in participants who had seldom
used cannabis, but were challenged with oral THC
relative to placebo, THC was shown to attenuate
activation in the right IFC and ACG and precuneus
bilaterally (Borgwardt et al. 2008).
In the present study, we supplemented our pre-
vious sample by recruiting additional participants,
using exactly the same criteria and methodology, to
investigate brain activation in those who experienced
transient psychotic symptoms after THC adminis-
tration, compared with those who did not. The ad-
ministration of cannabidiol, in addition to THC and
placebo, is not included in this paper, as it is not rel-
evant to the investigation in question. We hypothe-
sized that participants who developed transient
psychotic symptoms with THC would show diﬀeren-
tial activation relative to those that did not experience
psychotic symptoms in brain regions that have pre-
viously been implicated in the pathophysiology of
psychosis, such as the prefrontal, medial temporal and
ventral temporal cortex.
Method
Design
This was a double-blind, placebo-controlled within-
subject study, with a 1-month interval between
scans. The order of drug administration was pseudo-
randomized so that equal numbers followed each
drug sequence. The Joint South London andMaudsley
National Health Service and Institute of Psychiatry
Research Ethics Committee approved the protocol.
Each subject provided informed consent and was
given extensive written and verbal information about
the eﬀects of cannabis, including psychotic symptoms.
Participants
All 21 participants were healthy, native English-
speaking, right-handed males. The majority (90.5%)
were white British. Their ages ranged from 20 to
42 years. All of them had used cannabis on no more
than 25 occasions in their lifetime and none had used
cannabis in the previous 3 months.
Criterion for inclusion into the TP group was made
post hoc, on the basis of those who scored 3 or more on
at least three items of the Positive and Negative
Syndrome Scale (PANSS) positive subscale (Kay et al.
1987) at 2-h measurements. D’Souza et al. (2004),
in their THC challenge study, had used the same
criterion previously. Participants who scored below
these thresholds were classed as ‘non-psychotic ’ (NP).
We identiﬁed 11 who met the criteria for transient
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psychosis. All completed the scanning procedure, ex-
cept for one who became too anxious to stay in the
scanner. Therefore, the behavioural and symptomatic
data are based on 11 TP participants and the imaging
data on 10.
Participants were carefully screened and the details
of the procedures can be found in the supplementary
material. They were asked to abstain from any illicit
drug use during the study period, from alcohol and
coﬀee 24 and 12 h before, respectively, and cigarettes
on the morning of each session, as well as receiving a
urine drug screening prior to scans.
Procedure
Participants were examined at the start of each session
and their pulse and blood pressure were monitored.
They were given identical-looking red gelatine cap-
sules of either 10 mg of THC (99.6% pure ; THC-
Pharm, Germany) or placebo (ﬂour). Both participants
and researchers were blind to the content of the cap-
sules. The dose of THC was selected on the basis of
previous research (Chesher et al. 1990 ; Curran et al.
2002 ; Gray et al. 2008) to produce an eﬀect on region-
al brain activation without prominent intoxication.
Even though oral administration is known to indicate
an erratic absorption and inter-subject variability
(Grotenhermen, 2003), it was the preferred method in
this study in order to produce a slow peaking plasma
level for the duration of the imaging session
(Lemberger et al. 1971; Ohlsson et al. 1980).
Behavioural ratings
The behavioural eﬀects were evaluated at baseline
(before drug administration), +1 h (immediately be-
fore scanning),+2 h (immediately after scanning) and
at +3 h time points by using the Visual Analogue
Mood Scale (VAMS), State-Trait Anxiety Inventory
(STAI), Addiction Research Centre Inventory (ARCI),
Analogue Intoxication Scale (AIS), Cambridge
Depersonalization Scale and PANSS. Further infor-
mation on these scales is available in the supplemen-
tary material.
As the focus of this paper is to explore the diﬀer-
ences between those who become TP under THC and
those who do not, we mainly evaluated the baseline
and 2-h measurements, when the peak intoxication is
experienced following oral administration. The 3-h
measurements are also presented in the graphs.
Researchers stayed with the participants until all
their symptoms disappeared. In all cases symptoms
had resolved spontaneously within 2–3 h. No psycho-
pathological symptoms were reported in follow-up
checks the next day, and at 1 week and 1 month later.
Functional MRI paradigm – go/no-go
Participants practised the go/no-go task prior to
scanning to ensure familiarity. The task involves
motor response inhibition and selective attention.
Subjects are required to either execute or inhibit a
motor response according to the visual cues presented
on a screen. The task is described in detail in the sup-
plementary material.
Behavioural analyses
Data were recorded on SPSS version 20.0 (SPSS, Inc.,
USA) and analysed using Stata 11 (StataCorp LP,
USA). Descriptive statistics were used to summarize
the baseline variables. Age, years of education, and
cannabis, cigarette, alcohol and other drug use were
compared between the two groups using t tests (or
equivalent non-parametric Mann–Whitney U tests or
Fisher’s exact test). A multilevel model was used to
assess the eﬀect of THC on each outcome measure,
with subject included as a random eﬀect and time as a
ﬁxed eﬀect. A second multilevel model assessed the
diﬀerence between the TP and NP groups. The distri-
bution of each measure was assessed and no gross
violations of normality were found, thus making
transformations of the data unnecessary. Non-
parametric methods are not advisable in this situation
as they are unable to handle missing data. The multi-
level models used in our analysis are less restrictive
regarding missingness assumptions.
When investigating task performance, two further
multilevel models were run. The ﬁrst included the
main eﬀect of drug only, while group eﬀect and its
interaction with drug were also added in the second.
Image acquisition
Images were acquired on a 1.5-T Signa (GE, USA)
system at the Maudsley Hospital, London. T2*-
weighted images were acquired with a repetition time
(TR) of 1.8 s, echo time (TE) of 40 ms, ﬂip angle 90x in
16 planes (7 mm thick), parallel to the anterior com-
missure–posterior commissure line. To facilitate ana-
tomic localization of activation, a high-resolution
inversion recovery image dataset was also acquired,
with 3-mm contiguous slices and an in-plane resol-
ution of 3 mm (TR 16000 ms, inversion time 180 ms,
TE 80 ms).
Data processing and analysis
A complete description of image analysis including
pre-processing and non-parametric statistical model-
ling can be found in the supplementary material. A
non-parametric approach (XBAM v4; http://www.
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brainmap.co.uk) was used to analyse the imaging
data, as this method does not assume that the pop-
ulation distribution is Gaussian. It is diﬃcult to test
this assumption with neuroimaging data in small
groups, and, when tested, is often found to be violated
(Rabe-Hesketh et al. 1997 ; Thirion et al. 2007). Instead,
this approach uses median statistics to control outlier
eﬀects and employs permutation rather than normal
theory-based inference as recommended by Hayasaka
& Nichols (2003). The test statistic is computed by
standardizing for individual diﬀerence in residual
noise before embarking on second-level, multi-subject
testing, using robust permutation-based methods,
employing a mixed-eﬀects method. The group
activation maps for each task condition were com-
puted for THC and placebo by determining the me-
dian sum of squares ratio at each voxel and then
compared using non-parametric repeated-measures
analysis of co-variance, with a voxelwise threshold of
p=0.05. The clusterwise threshold was set such that
the total number of false-positive clusters per brain
volume was<1 per map and the p value at which this
occurred is reported.
Results
Of the 12 participants receiving THC in the ﬁrst ses-
sion and placebo in the second, six were classiﬁed as
being in the TP group. The order of drug adminis-
tration was reversed in the remaining nine partici-
pants, of whom ﬁve were subsequently included in the
TP group. There was no evidence of an order eﬀect,
and no signiﬁcant group diﬀerences with respect to
age or years of education (all p>0.1). Out of 21, 13 did
not smoke. A total of eight participants were current
tobacco smokers, but only two smoked more than 10
cigarettes per day and both of these were in the NP
group. Fisher’s exact test showed no signiﬁcant dif-
ference between the two groups in terms of cigarette
smoking, cannabis, alcohol and other drug use (all
p>1.00) (Table 1).
Symptom data
In all participants, a signiﬁcant change in the level of
the following outcome measures was observed 2 h
after the administration of THC: STAI (p<0.001),
ARCI (p<0.001), VAMS tranquillization subscale
(p=0.007), AIS (p<0.001) and each of the PANSS
subscales (pf0.001) (Fig. 1). For each of these meas-
ures an increase in score was observed, with the ex-
ception of VAMS tranquillization, which was lower at
2 h. The diﬀerences observed between baseline and 2 h
were only signiﬁcant when participants received THC,
rather than placebo.
There was no signiﬁcant diﬀerence between the TP
and NP groups on any symptom measure at baseline
or after placebo administration. However, 2 h after the
administration of THC, there was a signiﬁcant diﬀer-
ence between the groups for VAMS tranquillization
(p=0.031), PANSS negative (p=0.020) PANSS posi-
tive, general and total subscales (all pf0.001) ; no sig-
niﬁcant diﬀerence was found for the other behavioural
scales (Table 2, Fig. 2).
Physiological measures
Under the THC condition, there was no evidence of a
diﬀerence in heart rates between the two groups either
at baseline or 2 h after drug administration. However,
when looking at the eﬀect of the drug across all parti-
cipants, heart rate was signiﬁcantly increased at 2 h
after administration of either THC (pf0.001) or pla-
cebo (p=0.002). There were no signiﬁcant diﬀerences
between either systolic or diastolic blood pressure in
the two groups either at baseline or 2 h after adminis-
tering THC. Graphs of physiological measures are
provided in the supplementary material.
Task performance
There was a non-signiﬁcant trend suggesting that
THC increased inhibition errors among all partici-
pants (p=0.066). A signiﬁcant interaction was found
between group and drug condition (p=0.002).
Inhibition errors were signiﬁcantly higher in the TP
group than in the NP group (p<0.001), but only when
participants received THC. No signiﬁcant diﬀerences
were found for mean reaction time to ‘go’ trials be-
tween the THC and placebo conditions. A table on task
performance is provided in the supplementary ma-
terial.
Neuroimaging results
Task eﬀect
Under the placebo condition, no-go relative to oddball
trials were associated with activation in the right ACG,
prefrontal cortex and right middle temporal gyrus
(MTG) independent of group, but with a less con-
servative signiﬁcance threshold contrast (p<0.025;
uncorrected for<1 false-positive cluster).
Main eﬀect of drug
During no-go compared with oddball trials, across all
subjects, THC increased activation in the hippocam-
pus, the tail of the caudate nucleus and the insula in
the right hemisphere, relative to placebo. There were
no areas where THC was associated with reduced ac-
tivation relative to placebo.
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Main eﬀect of group
During no-go compared with oddball trials, indepen-
dent of drug, the TP group showed less activation than
the NP group in the right MTG (p<0.005; corrected
for <1 false-positive cluster) and the vermis of the
cerebellum (p<0.005 ; corrected for <1 false-positive
cluster). There were no areas where the TP
group showed greater activation than the NP group
(Fig. 3).
Grouprdrug interaction
There was a signiﬁcant interaction (p<0.01 ; corrected
for <1 false-positive cluster) between the eﬀects of
drug and group in the left parahippocampal gyrus
(PHG), MTG, superior temporal gyrus (STG) and in
the region spanning the right cerebellum and adjacent
fusiform gyrus. In all of these regions, relative to pla-
cebo, THC signiﬁcantly attenuated activation in the TP
group, whereas it increased it in the NP group.
Relative to placebo, THC also increased activation in
the right MTG in the TP group (p<0.01 ; corrected for
<1 false-positive cluster), but it attenuated activation
in the NP group (Fig. 4).
Discussion
We used functional magnetic resonance imaging to
investigate diﬀerential response to oral THC in a
group of healthy, seldom cannabis users and com-
pared the behavioural and imaging ﬁndings of those
who developed transient psychotic symptoms with
those who did not. We found signiﬁcant diﬀerences
between the two groups in the eﬀects of THC in the
left PHG, STG, MTG and cerebellum, where THC de-
creased activation in TPs, but increased it in NPs. In
the right MTG the reverse happened; THC increased
activation in the TPs and decreased it in the NPs. This
was accompanied by a higher error rate in the TPs,
relative to the NP group, during THC condition. TPs
also showed less activation than the NPs in the right
Table 1. Participants’ sociodemographic and substance-use comparisonsa
Transiently
psychotic (n=11)
Non-psychotic
(n=10)
THC in ﬁrst session, n 6 6
Mean age, years (S.D.) 26.76 (5.00) 25.70 (6.27)
Mean education, years (S.D.) 15.33 (3.64) 16.78 (4.15)
Employment, n (%)
Employed 8 (72.7) 3 (30.0)
Unemployed 0 (0) 1 (10.0)
Student 2 (18.2) 5 (50.0)
No details 1 (9.1) 1 (10.0)
Cannabis useb, n (%)
Experimental 7 (63.6) 5 (50.0)
Occasional 4 (36.4) 5 (50.0)
Cigarette use, n (%)
Non-smoker 7 (63.6) 6 (60.0)
Smoker 4 (36.4) 4 (40.0)
Alcohol usec, n (%)
Occasional 6 (54.6) 5 (50.0)
Moderate 5 (45.4) 5 (50.0)
Other drugs, n (%)
Not used 8 (72.7) 7 (70.0)
Used 3 (27.2) 3 (30.0)
THC, D9-Tetrahydrocannabinol ; S.D., standard deviation ; df, degrees of freedom.
aNo order eﬀect (x2=0.06, df=1, p=0.80) and no signiﬁcant group diﬀerences with
respect to age (Mann–Whitney U test : Z=x0.78, p=0.44), years of education
(t=0.79, df=16, p=0.44) and with Fisher’s exact test : use of cigarette smoking
(p=1.00), cannabis (p=0.67), alcohol (p=1.00) and other drug use (p=1.00).
b Experimental cannabis use=less than 10 times. Occasional use=10–25 times, in
lifetime.
c Occasional alcohol use=drinking at weekends, social events. Moderate
use=drinking at least three times per week.
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MTG and the vermis of the cerebellum, independent
of THC.
Symptomatic eﬀects of THC
As the groups were deﬁned in terms of their psychotic
experiences following THC, it is not surprising that
they diﬀered in their PANSS scores. Due to the small
sample size, however, formal corrections for multiple
testing were not possible. Instead we lowered the sig-
niﬁcance level from 5% to 1% at which the PANSS
positive, general and total scores remained signiﬁcant,
and the negative subscale showed a trend (p=0.02).
Therefore the negative scale result needs to be treated
with caution. Even though THC signiﬁcantly aﬀected
most measures in all participants, there were remark-
ably few signiﬁcant diﬀerences in the levels of
mood, anxiety and intoxication between the two
groups. This may suggest that the diﬀerential sensi-
tivity to the eﬀects of THC was particularly and
speciﬁcally related to psychotic symptoms. We cannot
exclude the possibility that the absence of diﬀerences
between the two groups in NP symptoms was due
to limited statistical power. However, that seems un-
likely, as the groups diﬀered signiﬁcantly not just
on psychotic symptom severity, but also in terms
of another behavioural measure : response inhibition
errors.
In terms of the acute eﬀects of THC, our ﬁndings
are in line with other challenge studies in which
healthy volunteers who received THC, either orally or
intravenously, experienced a broad range of transient
positive psychotic, negative psychotic and cognitive
symptoms (Curran et al. 2002 ; D’Souza et al. 2004 ;
Morrison et al. 2009). These studies also found
that psychotic symptoms were not correlated with
anxiety symptoms following THC. Signiﬁcant in-
creases in pulse rate occurred both in THC and pla-
cebo conditions, possibly due to the experimental
conditions.
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Fig. 1. Comparison of behavioural measures over time, in the D9-tetrahydrocannabinol (THC) condition : (a) Spielberger’s
State-Trait Anxiety Inventory ; (b) Addiction Research Centre Inventory ; (c) Analogue Intoxication Scale ; and (d) Visual
Analogue Mood Scale (VAMS) tranquillization category. Data are means, with standard errors represented by vertical bars.
Measurements were taken just before drug administration at baseline (0) and repeated 1, 2 and 3 h after drug administration.
When conditioning on THC, a comparison of transiently psychotic and non-psychotic at 2 h after drug administration showed a
signiﬁcant diﬀerence in the VAMS tranquillization category only (p=0.03).
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Task performance
We found a process-speciﬁc eﬀect of THC on the main
inhibitory measure of the task (commission/inhibition
errors), but not on the executive process of the task
(mean reaction time to ‘go’ trials). Across all partici-
pants THC increased inhibition errors at a trend-level
of signiﬁcance. Furthermore, there was a signiﬁcant
grouprdrug interaction on this measure, where TPs
made signiﬁcantly more commission errors than NPs.
This ﬁnding cannot be related to performance diﬀer-
ences, as we modelled only the correct trials. The
ﬁndings show, that the eﬀect of THC on impairing go/
no-go task performance is speciﬁc to the inhibitory
process and that this eﬀect is more pronounced in
those who develop transient psychosis. Our partici-
pants seldom used cannabis, whilst previously
both occasional and heavy users of cannabis have been
shown to have increased reaction time with
the stop signal task, which is considered to be indica-
tive of poor impulse control to single doses
of THC (Ramaekers et al. 2009). The ﬁnding of inhi-
bition deﬁcits in TPs is comparable with those
reported in people with schizophrenia and bipolar
disorder during the go/no-go task (Kiehl et al. 2000 ;
Fleck et al. 2011). Higher impulsivity, inability to sup-
press irrelevant acts and being unaware of making
errors are likely to originate from a poorly coordinated
response inhibition system and may be associated
with the formation of some of the psychotic symp-
toms.
Neural eﬀects of go/no-go task
Even though in our previous study (Borgwardt et al.
2008) relative to placebo, THC attenuated activation
in the right inferior frontal gyrus and the ACG,
here we found that the activation of the speciﬁc motor
response inhibition network occurred only with a
lenient threshold. However, consistent with the
results of previous studies (Borgwardt et al. 2008 ;
Bhattacharyya et al. 2010), we have again found that
THC signiﬁcantly increased activation in the right
hippocampus, tail of the caudate and insula. While the
latter two are key areas of inhibition, the hippocampus
is not (Chambers et al. 2009). These ﬁndings suggest
Table 2. Comparison of symptom scales between TP and NP groups at both baseline and 2 ha
Placebo THC
Time
Mean diﬀerence
between TP and
NP (95% CI) Z p
Mean diﬀerence
between TP and
NP (95% CI) Z p
STAI state Baseline x1.10 (x8.07 to 5.87) x0.31 0.76 x0.05 (x8.73 to 8.63) x0.01 0.99
2 h 0.31 (x6.71 to 7.33) 0.09 0.93 6.12 (x2.69 to 14.92) 1.36 0.17
ARCI Baseline 2.83 (x0.94 to 6.60) 1.47 0.14 1.67 (x2.68 to 6.02) 0.75 0.45
2 h 2.59 (x1.14 to 6.33) 1.36 0.17 1.47 (x2.88 to 5.82) 0.66 0.51
AIS score Baseline x0.06 (x1.70 to 1.59) x0.07 0.94 x0.34 (x2.20 to 1.52) x0.36 0.72
2 h 0.24 (x1.34 to 1.83) 0.30 0.76 0.76 (x1.14 to 2.66) 0.78 0.43
VAMS
tranquillization
Baseline x0.96 (x5.48 to 3.56) x0.42 0.68 0.65 (x4.46 to 5.75) 0.25 0.80
2 h x0.43 (x4.88 to 4.02) x0.19 0.85 x5.62 (x10.73 tox0.52) x2.16 0.03*
PANSS positive Baseline x0.30 (x0.70 to 0.10) x1.48 0.14 x0.15 (x2.55 to 2.24) x0.13 0.90
2 h 0.08 (x0.32 to 0.48) 0.40 0.69 6.94 (4.59–9.28) 5.81 <0.001*
PANSS negative Baseline x0.20 (x0.64 to 0.24) x0.88 0.38 x0.10 (x2.41 to 2.21) x0.08 0.93
2 h x0.02 (x0.46 to 0.43) x0.08 0.94 2.68 (0.42–4.94) 2.33 0.02*
PANSS general Baseline x0.19 (x1.11 to 0.73) x0.41 0.68 0.60 (x4.04 to 5.25) 0.25 0.80
2 h 0.48 (x0.44 to 1.40) 1.03 0.31 9.82 (5.35–14.28) 4.31 <0.001*
PANSS total Baseline x0.69 (x2.05 to 0.67) x0.99 0.32 x2.10 (x7.94 to 7.94) 0.10 1.00
2 h 0.55 (x0.82 to 1.91) 0.78 0.43 19.16 (11.40–26.92) 4.84 <0.001*
TP, Transiently psychotic ; NP, non-psychotic ; THC, D9-tetrahydrocannabinol ; CI, conﬁdence interval ; STAI, State-Trait
Anxiety Inventory ; ARCI, Addiction Research Centre Inventory ; AIS, Analogue Intoxication Scale ; VAMS, Visual Analogue
Mood Scale ; PANSS, Positive and Negative Syndrome Scale.
a Due to small sample size, multilevel model analyses were performed separately for THC and placebo. The only signiﬁcant
diﬀerence between the groups was seen in VAMS tranquillization (p=0.03) and all PANSS subscales : PANSS negative (pf0.02)
and the PANSS positive, general and total subscales (all pf0.001).
* p<0.05.
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increased brain-processing eﬀort during an inhibition
task in a more widespread manner involving brain
regions other than the speciﬁc response inhibition
network, as has been reported previously in subjects
who use cannabis on a regular basis (Tapert et al. 2007 ;
Roberts & Garavan, 2010). Our ﬁndings extend those
previous ﬁndings by showing that the up-regulation
eﬀect of these areas is already observed in people who
use cannabis seldomly and further support the view
that THC may be disrupting the neural mechanisms
involved with this task. Alternative neuroanatomic
recruitment such as involvement of the STG, MTG and
cerebellum have also been reported in a number of
studies carried out on patients with bipolar disorder
and schizophrenia during response inhibition tasks
(Fleck et al. 2011; Hughes et al. 2012).
Group eﬀect
The two groups diﬀered inherently in terms of their
task-related activation in the right MTG and the
vermis of the cerebellum, independent of THC, which
were reduced in the TPs. This is an interesting ﬁnding
which implies a trait diﬀerence between the groups.
As we excluded those with personal and family his-
tory of psychosis, it is unlikely that this ﬁnding reﬂects
these factors. Additionally, the task we used does not
normally involve the right MTG or the cerebellum. We
can tentatively suggest that the diﬀerences we found
may reﬂect a more general diﬀerence in participants’
vulnerability to transient psychosis or to inhibitory
dyscontrol and could be related to variations in
single nucleotide polymorphisms that are associated
with an increased risk of psychosis. However, our
sample was not large enough to investigate this. Some
recent studies focusing on early identiﬁcation of psy-
chosis have reported that the right MTG is implicated
in at-risk or high-risk groups (Fusar-Poli et al. 2010 ;
Meijer et al. 2011). Grey matter loss in the cerebellum
amongst ﬁrst-onset psychosis patients has also
been shown in a recent meta-analysis (Fusar-Poli et al.
2011). Other supporting evidence for the involvement
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Fig. 2. Comparison of Positive and Negative Syndrome Scale (PANSS) subscales, between the transiently psychotic and
non-psychotic groups under D9-tetrahydrocannabinol (THC) and placebo conditions : (a) positive symptoms ; (b) negative
symptoms ; (c) general psychopathology ; and (d) total score. Data are means, with standard errors represented by vertical bars.
A comparison of transiently psychotic and non-psychotic participants 2 h after drug administration showed signiﬁcant
diﬀerences in the PANSS negative subscale (p=0.02) and a highly signiﬁcant diﬀerence in all other subscales (all pf0.001). Note
that the y-axes have diﬀerent scales in the graphs.
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of this region to genetic vulnerability to psychosis is
found in a recently reported study, when a signiﬁcant
three-way interaction between two susceptibility
genes implicated in glutamate transmission (G72 and
DAAO) and the diagnosis of psychosis was detected at
the right MTG (Mechelli et al. 2012).
Diﬀerential neurophysiological processing of THC
Our other main ﬁnding was that, as hypothesized,
THC had a diﬀerent eﬀect on brain function in parti-
cipants who developed transient psychotic symptoms
from those who did not. These eﬀects were evident in
the left PHG, an area that has been implicated in
the pathophysiology of psychosis in post-mortem
(McDonald et al. 2000), neuropsychological (Marvel
et al. 2007), volumetric (Witthaus et al. 2009), functional
(Wolf et al. 2007) and neurochemical (Stone et al. 2010)
imaging studies. Eﬀects in this region in relation to
THC-induced psychosis are of particular interest be-
cause of the evidence that chronic cannabis use can
impair memory (Battisti et al. 2010b). Our group had
previously reported that THC increased para-
hippocampal activation bilaterally during an encoding
task (Bhattacharyya et al. 2009) and attenuated it dur-
ing an attentional salience task (Bhattacharyya et al.
2012b). Furthermore, structural and functional chan-
ges in the parahippocampal region are frequently
identiﬁed in relation to cannabis use (Lorenzetti et al.
2010 ; Martı´n-Santos et al. 2010). The ﬁnding that atte-
nuated left parahippocampal activity is observed only
in the TPs, but not in the NPs, provides further sup-
port that this region may be implicated in psychoses.
Additional diﬀerences were evident in the left
middle/superior temporal cortices and in the cer-
ebellum, areas that are implicated as key regions in
schizophrenia (for reviews, see Honea et al. 2005 ;
Smieskova et al. 2010 ; Jardri et al. 2011). The STG, as
well as the cerebellum, has been implicated in
inhibitory control (Rubia et al. 2007). The increased
inhibition error rate in the TP group together with the
increased activation in these two inhibition-related
areas may suggest that the TP group had to work
harder to maintain their inhibitory capacity, which
was still below the level of that in the NP group.
Conversely, THC increased activation in the right
MTG in the TPs, whilst it attenuated it in the NPs. It is
interesting that this area is diﬀerentially activated be-
tween the groups whether or not THC was present. It
is diﬃcult to interpret the two ﬁndings in relation to
one another as they involve diﬀerent analyses involv-
ing the same region.
In all of these regions, the eﬀect of THC on acti-
vation in the group that experienced psychotic symp-
toms was in the opposite direction to that in the group
that did not develop psychotic symptoms. The
underlying processes for this dissociated eﬀect will
require further research and replication. Interestingly,
a ketamine challenge study with healthy volunteers
also reported a compelling consistency between the
task, region, symptom associations and those reported
in patients with schizophrenia (Honey et al. 2008).
Tal (x) Tal (y) Tal (z) Side Cerebral region 
58 –22 15 Right Right middle temporal gyrus
–7 –67 –24 – Vermis of cerebellum
(a) (b)
Fig. 3. Trait diﬀerences. Analysis of all subjects, independent of drug condition, showed signiﬁcant diﬀerences between the two
groups in two regions. (a) Crosshair showing that activation in the right middle temporal gyrus is attenuated in the transiently
psychotic (TP) group in comparison with the non-psychotic (NP) group (TP<NP, p<0.007, corrected for<1 false-positive
cluster). (b) Crosshair showing that activation in the vermis of the cerebellum is attenuated in the TP group in comparison with
the NP group (TP<NP, p<0.005, corrected for<1 false-positive cluster). The left side of the brain is shown on the left side of
the images. All coordinates in Talairach (Tal) space.
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To our knowledge, the present study is the ﬁrst to
demonstrate neurobiological diﬀerences that may
contribute to the diﬀerential sensitivity to the psycho-
togenic eﬀects of cannabis in healthy participants. Our
ﬁndings imply that there is an association between
individual variability in brain response and sub-
sequent transitory psychotic symptom formation.
Even though THC only transiently produced psy-
chotic symptoms in some, the brain regions that were
up-regulated are also those critically implicated in
schizophrenia. Whilst acknowledging that transient
psychosis is not the same as a full-blown psychosis,
there may be varying degrees of risk in response to the
psychotogenic eﬀects of THC. How THC modulates
speciﬁc brain regions can also provide information on
symptom formation. Given the size of the problem
universally, similar studies with larger samples are
required to understand the basis of diﬀerential neural
responses to THC to inform the ongoing public health
debate about the risks of cannabis use, as well as
leading to the development of interventions designed
to reduce its use, particularly targeting those most at
risk.
Limitations
This study has a modest sample size. Studies of this
type are logistically diﬃcult when participants, who
seldom use cannabis, are asked to attend more than
one study session. However, we have used non-para-
metric, repeated-measures analyses to obtain more
robust ﬁndings in order to compensate for the low
numbers (Brammer et al. 1997 ; Bullmore et al. 1999).
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21 –43 –59 –2 L Middle temporal gyrus
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Fig. 4. Interaction between the transiently psychotic (TP) and non-psychotic (NP) groups and drug conditions [D9-
tetrahydrocannabinol (THC) versus placebo]. Plots (a), (b) and (c) show that the administration of THC attenuated activation in
the left parahippocampal gyrus/fusiform gyrus (a crosshair), left middle temporal gyrus/superior temporal sulcus (b crosshair)
and right cerebellum/fusiform gyrus (c crosshair) in the TP group, whilst it increased activation in the same region in the NP
group (p=0.01). Plot (d) shows that THC modulated activation by increasing it in the right middle temporal gyrus (d crosshair)
in the TP group, whilst it attenuated it in the NP group (p=0.01). Data are means indexed by the mean sum of squares ratio, with
standard errors represented by vertical bars. The left side of the brain is shown on the left side of the images. All coordinates in
Talariach (Tal) space. a In the NP group THC did the reverse activity in these regions.
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The use of PANSS is another limitation, as this scale is
not designed for transient psychosis, even though our
participants experienced frank hallucinations and de-
lusions temporarily.
Supplementary material
For supplementary material accompanying this paper
visit http://dx.doi.org/10.1017/S0033291712001924.
Acknowledgements
The present study was supported by a Joint Medical
Research Council/Priory clinical research training
fellowship to S.B. and support from the Psychiatry
Research Trust, UK. We are grateful to Glynis
Ivin (Department of Pharmacology, the Maudsley
Hospital), for the storing, blinding procedure and
dispensing of the THC and placebo.
Declaration of Interest
None.
References
Arseneault L, Cannon M, Murray R, Poulton R, Caspi A,
Moﬃtt TE (2002). Cannabis use in adolescence and risk for
adult psychosis : longitudinal prospective study. British
Medical Journal 325, 1212–1213.
Battisti RA, Roodenrys S, Johnstone SJ, Pesa N,
Hermens DF, Solowij N (2010a). Chronic cannabis users
show altered neurophysiological functioning on Stroop
task conﬂict resolution. Psychopharmacology 212, 613–624.
Battisti RA, Roodenrys S, Johnstone SJ, Respondek C,
Hermens DF, Solowij N (2010b). Chronic use of cannabis
and poor neural eﬃciency in verbal memory ability.
Psychopharmacology 209, 319–330.
Bhattacharyya S, Atakan Z, Martı´n-Santos R, Crippa JA,
Kambeitz J, Prata D, Williams S, BrammerM, Collier DA,
McGuire PK (2012a). Preliminary report of biological basis
of sensitivity to the eﬀects of cannabis on psychosis : AKT1
and DAT1 genotype modulates the eﬀects of D-9-
tetrahydrocannabinol on midbrain and striatal function.
Molecular Psychiatry. Published online 31 January 2012.
doi :10.1038/mp.2011.
Bhattacharyya S, Crippa JA, Allen P, Martı´n-Santos R,
Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J,
O’Carroll C, Seal ML, Giampietro V, Brammer M,
Zuardi AW, Atakan Z, McGuire PK (2012b). Induction of
psychosis by D9-tetrahydrocannabinol reﬂects modulation
of prefrontal and striatal function during attentional
salience processing. Archives of General Psychiatry 69, 27–36.
Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martı´n-Santos
R, Nosarti C, O’Carroll C, Allen P, Seal ML, Fletcher PC,
Crippa JA, Giampietro V, Mechelli A, Atakan Z,
McGuire P (2009). Modulation of mediotemporal and
ventrostriatal function in humans by D9-
tetrahydrocannabinol : a neural basis for the eﬀects of
Cannabis sativa on learning and psychosis. Archives of
General Psychiatry 66, 442–451.
Bhattacharyya S, Morrison PD, Fusar-Poli P,
Martı´n-Santos R, Borgwardt S, Winton-Brown T,
Nosarti C, O’Carroll CM, Seal M, Allen P, Mehta MA,
Stone JM, Tunstall N, Giampietro V, Kapur S,
Murray RM, Zuardi AW, Crippa JA, Atakan Z,
McGuire P (2010). Opposite eﬀects of D-9-
tetrahydrocannabinol and cannabidiol on human brain
function and psychopathology. Neuropsychopharmacology
35, 764–774.
Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P,
Crippa JA, Seal ML, Fraccaro V, Atakan Z,
Martı´n-Santos R, O’Carroll C, Rubia K, McGuire PK
(2008). Neural basis of D-9-tetrahydrocannabinol and
cannabidiol : eﬀects during response inhibition. Biological
Psychiatry 64, 966–973.
Brammer MJ, Bullmore ET, Simmons A, Williams SCR,
Grasby PM, Howard RJ, Woodruﬀ PWR, Rabe-Hesketh S
(1997). Generic brain activation mapping in fMRI : a
non-parametric approach. Magnetic Resonance Imaging 15,
763–770.
Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S,
Taylor E, Brammer MJ (1999). Global, voxel and
cluster tests, by theory and permutation, for a
diﬀerence between two groups of structural MR
images of the brain. IEEE Transactions on Medical Imaging
18, 32–42.
Cascini F, Aiello C, Di Tanna G (2011). Increasing delta-9-
tetrahydrocannabinol (D-9-THC) content in herbal
cannabis over time : systematic review and meta-analysis.
Current Drug Abuse Reviews 5, 32–40.
Caspi A, Moﬃtt TE, Cannon M, McClay J, Murray R,
Harrington H, Taylor A, Arseneault L, Williams B,
Braithwaite A, Poulton R, Craig IW (2005). Moderation of
the eﬀect of adolescent-onset cannabis use on adult
psychosis by a functional polymorphism in the catechol-O-
methyltransferase gene : longitudinal evidence of a
gener environment interaction. Biological Psychiatry 57,
1117–1127.
Chambers CD, Garavan, Bellgrove MA (2009). Insights into
the neural basis of response inhibition from cognitive and
clinical neuroscience. Neuroscience and Biobehavioural
Reviews 33, 631–646.
Chesher GB, Bird KD, Jackson DM, Perrignon A,
Starmer GA (1990). The eﬀects of orally administered delta
9-tetrahydrocannabinol in man on mood and performance
measures : a dose–response study. Pharmacology,
Biochemistry and Behavior 35, 861–864.
Curran HV, Brignell C, Fletcher S, Middleton P, Henry J
(2002). Cognitive subjective dose–response eﬀects of acute
oral D9-tetrahydrocannabinol (THC) in infrequent cannabis
users. Psychopharmacology 164, 61–70.
Degenhardt L, Coﬀey C, Carlin JB, Swift W, Moore E,
Patton GC (2010). Outcomes of occasional cannabis
use in adolescence : 10-year follow-up study in
Victoria, Australia. British Journal of Psychiatry 196,
290–295.
Variation in the psychotogenic eﬀects of D9-tetrahydrocannabinol 1265
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291712001924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:12:21, subject to the Cambridge Core terms of use, available at
D’Souza DC, Perry E, MacDougall L, Ammerman Y,
Cooper TB, Wu YT, Braley G, Gueorguieva R, Krystal JH
(2004). The psychotomimetic eﬀects of intravenous delta-9-
tetrahydrocannabinol in healthy individuals :
implications for psychosis. Neuropsychopharmacology 29,
1558–1572.
D’Souza DC, Sewell RA, Ranganathan M (2009). Cannabis
and psychosis/schizophrenia : human studies. European
Archives of Clinical Neurosciences 259, 413–431.
Enticott PG, Ogloﬀ JR, Bradshaw JL (2008). Response
inhibition and impulsivity in schizophrenia. Psychiatry
Research 157, 251–254.
Fleck DE, Kotwal R, Eliassen JC, Lamy M, DelBello MP,
Adler CM, Durling M, Cerullo MA, Strakowski SM
(2011). Preliminary evidence for increased
frontosubcortical activation on a motor impulsivity task in
mixed episode bipolar disorder. Journal of Aﬀective
Disorders 133, 333–339.
Fusar-Poli P, Broome MR, Matthiasson P, Woolley JB,
Johns LC, Tabraham P, Bramon E, Valmaggia L,
William SC, McGuire P (2010). Spatial working memory
in individuals at high risk for psychosis : longitudinal fMRI
study. Schizophrenia Research 123, 45–52.
Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ,
Allen P, Martı´n-Santos R, Seal M, Surguladze SA,
O’Carroll C, Atakan Z, Zuardi AW, McGuire PK (2009).
Distinct eﬀects of D9-tetrahydrocannabinol and
cannabidiol on neural activation during emotional
processing. Archives of General Psychiatry 66, 95–105.
Fusar-Poli P, Radua J, McGuire P, Borgwardt S (2011).
Neuroanatomical maps of psychosis onset : voxel-wise
meta-analysis of antipsychotic-naı¨ve VBM studies.
Schizophrenia Bulletin. Published online 17 November 2011.
doi :10.1093/schbul/sbr134.
Gray KM, Hart CL, Christie DK, Upadhyaya HP (2008).
Tolerability and eﬀects of oral D9-tetrahydrocannabinol in
older adolescents with marijuana use disorders.
Pharmacology, Biochemistry and Behavior 91, 67–70.
Green B, Kavanagh D, Young R (2003). Being stoned : a
review of self-reported cannabis eﬀects. Drug and Alcohol
Review 22, 453–460.
Grotenhermen F (2003). Pharmacokinetics and
pharmacodynamics of cannabinoids. Clinical
Pharmacokinetics 42, 327–360.
Gruber SA, Yurgelun-Todd DA (2005). Neuroimaging of
marijuana smokers during inhibitory processing : a pilot
investigation. Brain Research. Cognitive Brain Research 23,
107–118.
Hayasaka S, Nichols TE (2003). Validating cluster size
inference : random ﬁeld and permutation methods.
Neuroimage 20, 2343–2356.
Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R,
Wittchen HU, van Os J (2004). Prospective cohort study of
cannabis use, predisposition for psychosis, and psychotic
symptoms in young people. British Medical Journal 330,
11–14.
Hester R, Nestor L, Garavan H (2009). Impaired error
awareness and anterior cingulate cortex hypoactivity in
chronic cannabis users. Neuropsychopharmacology 4,
2450–2458.
Honea R, Crow TJ, Passingham D, Mackay CE (2005).
Regional deﬁcits in brain volume in schizophrenia : a meta-
analysis of voxel-based morphometry studies. American
Journal of Psychiatry 162, 2233–2245.
Honey GD, Corlett PR, Absolam AR, Lee M,
Pomarol-Clotet E, Murray GK, McKenna PJ,
Bullmore ET, Menon DK, Fletcher PC (2008). Individual
diﬀerences in psychotic eﬀects of ketamine are predicted
by brain function measure under placebo. Journal of
Neuroscience 28, 6295–7303.
Huddy VC, Aron AR, Harrison M, Barnes TR, Robbins TW,
Joyce EM (2009). Impaired conscious and preserved
unconscious inhibitory processing in recent onset
schizophrenia. Psychological Medicine 39, 907–916.
Hughes ME, Fulham WR, Johnston PK, Michie PT (2012).
Stop-signal response inhibition in schizophrenia :
behavioural, event-related potential and functional
neuroimaging data. Biological Psychiatry 89, 220–231.
Jardri R, Pouchet A, Pins D, Thomas P (2011). Cortical
activations during auditory verbal hallucinations in
schizophrenia : a coordinate-based meta-analysis. American
Journal of Psychiatry 168, 73–81.
Kay SR, Fiszbein A, Opler LA (1987). The Positive and
Negative Syndrome Scale (PANSS) for schizophrenia.
Schizophrenia Bulletin 13, 261–276.
Kiehl KA, Smith AM, Hare RD, Liddle PF (2000). An
event-related potential investigation of response inhibition
in schizophrenia and psychopathy. Biological Psychiatry 48,
210–221.
Lemberger L, Axelrod J, Kopin IJ (1971). Metabolism
disposition of D9-tetrahydrocannabinol in man.
Pharmacological Review 23, 371–380.
Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M
(2010). Structural MRI ﬁndings in long-term cannabis
users : what do we know? Substance Use and Misuse 45,
1787–1808.
Martı´n-Santos R, Fagundo AB, Crippa JA, Atakan Z,
Bhattacharyya S, Allen P, Fusar-Poli P, Borgwardt S,
Seal M, Busatto GF, McGuire P (2010). Neuroimaging in
cannabis use : a systematic review of the literature.
Psychological Medicine 40, 383–398.
Marvel CL, Turner BM, O’Leary DS, Johnson HJ, Pierson
RK, Pnoto LL, Andreasen NC (2007). The neural correlates
of implicit sequence learning in schizophrenia.
Neuropsychology 21, 761–777.
McDonald B, Highley JR, Walker MA, Herron BM,
Cooper SJ, Esiri MM, Crow TJ (2000). Anomalous
asymmetry of fusiform and parahippocampal gyrus gray
matter in schizophrenia : a postmortem study. American
Journal of Psychiatry 157, 40–47.
McGuire PK, Jones P, Harvey I, Williams M, McGuﬃn P,
Murray RM (1995). Morbid risk of schizophrenia for
relatives of patients with cannabis-associated psychosis.
Schizophrenia Research 15, 277–281.
Mechelli A, Fusar-Poli P, Papagni SA, Tognin S,
Kambeitz J, Fu C, Picchioni M, Walshe M,
Toulopoulou T, Bramon E, Murray R, McGuire P (2012).
Genetic vulnerability to psychosis and cortical function :
epistatic eﬀects between DAAO and G72. Current
Pharmacological Design 18, 510–517.
1266 Z. Atakan et al.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291712001924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:12:21, subject to the Cambridge Core terms of use, available at
Meijer JH, Schmitz N, Nieman DH, Becker HE,
van Amelsvoort TA, Dingemans PM, Linszen DH,
de Haan L (2011). Semantic ﬂuency deﬁcits and
reduced grey matter before transition to psychosis : a
voxelwise correlational analysis. Psychiatry Research 194,
1–6.
Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE,
Jones PB, Burke M, Lewis G (2007). Cannabis use and risk
of psychotic or aﬀective mental health outcomes : a
systematic review. Lancet 370, 319–328.
Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW,
Powell JF, Kapur S,Murray RM (2009). The acute eﬀects of
synthetic intravenous D9-tetrahydrocannabinol on
psychosis, mood and cognitive functioning. Psychological
Medicine 39, 1607–1616.
Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE,
Gillespie HK (1980). Plasma delta-9 tetrahydrocannabinol
concentrations clinical eﬀects after oral intravenous
administration smoking. Clinical Pharmacology and
Therapeutics 28, 409–416.
Peters BD, de Koning P, Dingemans P, Becker H,
Linszen DH, de Haan L (2009). Subjective eﬀects of
cannabis before the ﬁrst psychotic episode. Australian and
New Zealand Journal of Psychiatry 43, 1155–1162.
Rabe-Hesketh S, Bullmore ET, Brammer MJ (1997). The
analysis of functional magnetic resonance images.
Statistical Methods in Medical Research 6, 215–237.
Ramaekers JG, Kauert G, Theunissen EL, Toennes SW,
Moeller MR (2009). Neurocognitive performance during
acute THC intoxication in heavy and occasional cannabis
users. Journal of Psychopharmacology 23, 266–277.
Roberts GM, Garavan H (2010). Evidence of increased
activation underlying cognitive control in ecstasy and
cannabis users. Neuroimage 15, 429–435.
Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ,
Simmons A, Taylor E, Andrew C, Giampietro V,
Sharma T (2001a). An fMRI study of reduced left
prefrontal activation in schizophrenia during normal
inhibitory function. Schizophrenia Research 52, 47–55.
Rubia K, Russell T, Overmeyer S, Brammer MJ,
Bullmore ET, Sharma T, Simmons A, William SC,
Giampetro V, Andrew CM, Taylor E (2001b). Mapping
motor inhibition : conjunctive brain activations across
diﬀerent versions of go/no-go and stop tasks. Neuroimage
13, 250–261.
Rubia K, Smith AB, BrammerMJ, Taylor E (2007). Temporal
lobe dysfunction in medication-naı¨ve boys with attention-
deﬁcit/hyperactivity disorder during attention allocation
and its relation to response variability. Biological Psychiatry
62, 999–1006.
Simmonds DJ, Pekar JJ, Mostofsky SH (2008). Meta-analysis
of go/no-go tasks demonstrating that fMRI activation
associated with response inhibition task is task-dependent.
Neuropsychologia 46, 224–232.
Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K,
Stieglitz RD, Drewe J, Radue EW, McGuire PK,
Riecher-Ro¨ssler A, Borgwardt SJ (2010). Neuroimaging
predictors of transition to psychosis – a systematic review
and meta-analysis. Neuroscience and Biobehavioral Reviews
34, 1207–1222.
Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G,
Schreudergoidheijt B, Lewis S (2008). Cannabis-induced
psychotic-like experiences are predicted by high
schizotypy. Conﬁrmation of preliminary results in a large
cohort. Psychopathology 41, 371–378.
Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P,
Lythgoe DJ, O’Gorman RL, McLean MA, Barker GJ,
McGuire P (2010). Altered relationship between
hippocampal glutamate levels and striatal dopamine
function in subjects at ultra high risk of psychosis. Biological
Psychiatry 68, 599–602.
Tapert SF, Schweinsburg AD, Drummond SPA, PaulusMP,
Brown SA, Yang TT, Frank LR (2007). Functional MRI of
inhibitory processing in abstinent adolescent marijuana
users. Psychopharmacology 194, 173–183.
Thirion B, Pinel P, Tucholka A, Roche A, Ciuciu P,
Mangin JF, Poline JB (2007). Structural analysis of fMRI
data revisited : improving the sensitivity and reliability of
fMRI group studies. IEEE Transactions on Medical Imaging
26, 1256–1269.
Thomas H (1996). A community survey of adverse eﬀects of
cannabis use. Drug and Alcohol Dependence 42, 201–207.
Turken AU, Vuilleumier P, Mathalon DH, Swick D,
Ford JM (2003). Are impairments of action monitoring and
executive control true dissociative dysfunctions in patients
with schizophrenia? American Journal of Psychiatry 160,
1881–1883.
van Winkel R; Genetic Risk and Outcome of
Psychosis (GROUP) Investigators (2011). Family-based
analysis of genetic variation underlying psychosis-
inducing eﬀects of cannabis : sibling analysis and proband
follow-up. Archives of General Psychiatry 68, 148–157.
Winton-Brown TT, Allen P, Bhattacharrya S, Borgwardt SJ,
Fusar-Poli P, Crippa JA, Seal M, Martı´n-Santos R,
Ffytche D, Zuardi AW, Atakan Z, McGuire PK (2011).
Modulation of auditory and visual processing by delta-9-
tetrahydrocannabinol and cannabidiol : an fMRI study.
Neuropsychopharmacology 36, 1340–1348.
Witthaus H, Kaufmann C, Bohner G, Ozgurdal S,
Gudlowski Y, Gallinat J, Ruhrmann S, Brune M, Heinz
A, Klingebiel R, Juckel G (2009). Gray matter
abnormalities in subjects at ultra-high risk for
schizophrenia and ﬁrst-episode schizophrenic patients
compared to healthy controls. Psychiatry Research 173,
163–169.
Wolf DH, Gur RC, Valdez JN, Loughead J, Elliott MA,
Gur R, Ragland JD (2007). Alterations of fronto-temporal
connectivity during word encoding in schizophrenia.
Psychiatry Research 154, 221–232.
Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G
(2002). Self reported cannabis use as a risk factor for
schizophrenia in Swedish conscripts of 1969 : historical
cohort study. British Medical Journal 325,
1199–1201.
Variation in the psychotogenic eﬀects of D9-tetrahydrocannabinol 1267
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291712001924
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 14:12:21, subject to the Cambridge Core terms of use, available at
